Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15284739 | 0.81 | HTT (0.50) | HTTCYP1A2MEN1KMT2ACACNA1F | |
| SCHEMBL9461101 | 0.81 | HTT (0.50) | HTTCYP1A2MEN1KMT2ACACNA1F | |
| SCHEMBL3559987 | 0.80 | HTT (0.49) | HTTCYP1A2CA1CA2MEN1 | |
| SCHEMBL13733197 | 0.80 | HTT (0.49) | HTTCYP1A2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL21547848 | 0.80 | NPSR1 (0.43) | HTTKMT2AALDH1A1MAPT | |
| SCHEMBL2254343 | 0.79 | HTT (0.48) | HTTCYP1A2MEN1KMT2ACACNA1F | |
| SCHEMBL1815124 | 0.79 | HTT (0.48) | HTTCYP1A2MEN1KMT2ACACNA1F | |
| Hydrochloric Acid SCHEMBL4493041 | 0.79 | HTT (0.48) | HTTCYP1A2CA1CA2MEN1 | |
| SCHEMBL12410861 | 0.79 | HTT (0.48) | HTTCYP1A2MEN1KMT2ACACNA1F | |
| Hydrochloric Acid SCHEMBL3559985 | 0.79 | HTT (0.48) | HTTCYP1A2CA1CA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113272309-B | Tricyclic inhibitors of hepatitis b virus | 圣拉斐尔医院有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| CN-111556871-B | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-11-08 | — | — | US | disclosed |
| CN-111465410-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-111526890-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-3723808-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| US-7456210-B2 | Benzyloxy derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456210-B2 | Benzyloxy derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070249655-A1 | 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones | KESTELEYN BART R R | 2007-10-25 | — | — | US | disclosed |
| US-20070249655-A1 | 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones | KESTELEYN BART R R | 2007-10-25 | — | — | US | disclosed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | disclosed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | disclosed |
| US-6465462-B1 | COGNITION ENHANCEMENT FOR DEMENTING ILLNESSES SUCH AS ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. | 2002-10-15 | — | — | US | disclosed |
| EP-0915877-A1 | SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABA A?$g(a)5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004560-A1 | SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABAAα5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
| US-3969365-A | ANTIINFLAMMATORY, HYPOGLYCEMIC | E. R. SQUIBB & SONS, INC. (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | PDE3B, PDE1B, PDE12 | HTT 551/4885CYP1A2 316/4885CA12 4304/4885 |
| US-20070249655-A1 | 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones | CYP8B1, CYP2S1, CYC1 | HTT 1603/4885CYP1A2 14/4885CA12 4872/4885 |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | HTT 1345/4885CYP1A2 157/4885CA12 4726/4885 |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | PDE1B, PDE3B, PDE1A | HTT 2881/4885CYP1A2 96/4885CA12 3903/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | HTT 4516/4885CYP1A2 935/4885CA12 4344/4885 |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | PNPO, CYP2D6, DPYD | HTT 1572/4885CYP1A2 61/4885CA12 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.